Contact SCGE




Gene Therapy Trial Report

Summary

Safety and Pharmacodynamics of GNSC-001 Intra-articular Injection for Knee Osteoarthritis


NCTID NCT05835895 (View at clinicaltrials.gov)
Description
Development Status Active
Indication Osteoarthritis, Knee
Disease Ontology Term DOID:8398
Compound Name GNSC-001
Compound Description AAV-CMV-IL1RN
Sponsor Genascence Corporation
Funder Type Industry
Recruitment Status
Active not recruiting
Enrollment Count 67 (ACTUAL)
Results Posted Not Available

Therapy Information


Target Gene/Variant IL1RN
Therapy Type Gene transfer
Therapy Route In-vivo
Mechanism of Action Overexpression of protective allele/gene
Route of Administration Intraarticular
Drug Product Type Viral vector
Delivery System Viral transduction
Vector Type AAV2.5
Editor Type none
Dose 1 1E11 vg/knee
Dose 2 1E12 vg/knee
Dose 3 1E13 vg/knee

Study Record Dates


Current Stage Phase1
Submit Date 2023-04-19
Completion Date 2029-05
Last Update 2025-08-01

Participation Criteria


Eligible Age 40 Years - 75 Years
Standard Ages Adult, Older adult
Sexes Eligible for Study ALL
Eligibility Criteria
Key Inclusion Criteria: * OA in at least one knee (the 'target knee'), confirmed using centrally read X-ray with a Kellgren-Lawrence (KL) score of 2 or 3 * Western Ontario \& McMaster University Osteoarthritis Index (WOMAC) pain score ≥ 20 (on a 50-point numerical rating scale) in the target knee during the seven days prior to Screening * Persistent moderate to severe symptoms in the target knee, despite failure or intolerance of a 3-month trial of at least 2 conservative therapies (e.g., activity modification, weight loss, physical therapy, opioids, and anti-inflammatory medications, and injection of hyaluronic acid or steroids) * Successful extraction of synovial fluid at Screening * Negative pregnancy test at Screening and Baseline (subjects of childbearing potential \[SOCBP\]) Key Exclusion Criteria: * Current or documented history of inflammatory arthritis (such as gout or rheumatoid arthritis), inflammation of connective tissue, or other immunological disease * Any form of joint degeneration as part of another syndrome (e.g., Ehler's Danlos, Stickler syndrome, etc.) * Surgery in the target knee within the 6 months prior to screening * Previous partial or total joint replacement in target knee * Significant and clinically evident malalignment of the target knee that would impact the subject's function, as determined by the Investigator * Body mass index (BMI) \> 38 kg/m2 * Clinically significant abnormal laboratory values at Screening in laboratory parameters that in the opinion of the Investigator, could represent a potential risk to participant safety: * Plans to have, elective surgery of other joints or spine or intra-articular injections in the target knee, within the next 12 months
View Inclusion and Exclusion Criteria at ClinicalTrials.gov

Locations


No.of Trial Sites 9
Locations United States

Regulatory Information


Has US IND True
FDA Designations Fast Track, Regenerative Medicine Advanced Therapy
Recent Updates The last patient exited the study in March 2025, and data are being analyzed

Resources/Links